IP Library Granted Patent US 8,217,047
Granted Patent B2
US 8,217,047 · App. 12/472,738 · Granted Jul 10, 2012

Therapeutic methods and compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,217,047
App. No.
12/472,738
Granted
Jul 10, 2012
Kind
B2
Abstract

The invention provides diketopiperazines of formula I. The invention also provides pharmaceutical compositions comprising the diketopiperazines, or pharmaceutically-acceptable salts or prodrugs thereof, as the active ingredient. The invention further provides therapeutic treatments that utilize the diketopiperazines of formula I, including inhibition of a proliferative disease or condition, inhibition of angiogenesis, treatment of an angiogenic disease or condition, treatment of cancer and precancerous conditions, treatment of a fibrotic disorder, treatment of a viral infection, treatment of an Akt-mediated disease or condition, inhibition of the production, release or both of matrix metalloproteinase-9, and inhibition of Akt activation.

Claims (38)

1. A diketopiperazine of the following formula or a pharmaceutically-acceptable salt thereof:

wherein:

R 1 is:

(a) a side chain of an amino acid, wherein the amino acid is glycine, alanine, valine, norvaline, α-aminoisobutyric acid, 2,4-diaminobutyric acid, 2,3-diaminobutyric acid, leucine, isoleucine, norleucine, serine, homoserine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxylysine, histidine, arginine, homoarginine, citrulline, phenylalanine, p-aminophenylalanine, tyrosine, tryptophan, thyroxine, cysteine, homocysteine, methionine, penicillamine or ornithine;

(b) —CH 2 —CH 2 —CH 2 — or —CH 2 —CH(OH)—CH 2 — and together with the adjacent ring nitrogen forms proline or hydroxyproline; or

(c) a derivative of a side chain of an amino acid, wherein the amino acid is one of those recited in (a), and the derivatized side chain has:

(i) an —NH 2 group replaced by an —NHR 3 or —N(R 3 ) 2 group, wherein each R 3 may independently be a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, arylalkyl or heteroaryl;

(ii) an —OH group replaced by an —O—PO 3 H 2 or —OR 3 group, wherein each R 3 may independently be a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, arylalkyl or heteroaryl;

(iii) a —COOH group replaced by a —COOR 3 group, wherein each R 3 may independently be a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, arylalkyl or heteroaryl;

(iv) a —COOH group replaced by a —CON(R 4 ) 2 group, wherein each R 4 may independently be H or a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, arylalkyl or heteroaryl;

(v) an —SH group replaced by —S—S—CH 2 —CH(NH 2 )—COOH or —S—S—CH 2 —CH 2 —CH(NH 2 )—COOH;

(vi) a —CH 2 — group replaced by a —CH(NH 2 )— or a —CH(OH)— group;

(vii) a —CH 3 group replaced by a —CH 2 —NH 2 or a —CH 2 —OH group; and/or

(viii) an H which is attached to a carbon atom replaced by a halogen;

R 2 has formula II, III or IV:

wherein:

each R 5 is independently aryl, heteroaryl, alkyl, cycloalkyl, heterocycloalkyl, alkoxy, aryloxy, acyl, carboxyl, hydroxyl, halogen, amino, nitro, sulfo or sylfhydryl, wherein each alkyl is optionally substituted with hydroxyl, amino or sulfhydryl;

n is from 0 to 5; and

R 6 is hydrogen or lower alkyl.

2. The diketopiperazine of claim 1 wherein:

R 1 is:

(d) a side chain of an amino acid, wherein the amino acid is glycine, alanine, valine, norvaline, α-aminoisobutyric acid, 2,4-diaminobutyric acid, 2,3-diaminobutyric acid, leucine, isoleucine, norleucine, serine, homoserine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxylysine, histidine, arginine, homoarginine, citrulline, phenylalanine, p-aminophenylalanine, tyrosine, tryptophan, thyroxine or ornithine; or

(e) a derivative of a side chain of an amino acid, wherein the amino acid is one of those recited in (d), and the derivative of the side chain is one of those recited in part (c) of claim 1 ; and

R 2 has formula II or III.

3. The diketopiperazine of claim 2 wherein R 1 is:

(f) a side chain of an amino acid, wherein the amino acid is glycine, alanine, valine, norvaline, α-aminoisobutyric acid, 2,4-diaminobutyric acid, 2,3-diaminobutyric acid, leucine, isoleucine, norleucine, serine, homoserine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxylysine, arginine, homoarginine, citrulline or ornithine; or

(g) a derivative of a side chain of an amino acid, wherein the amino acid is one of those recited in (f), and the derivative of the side chain is one of those recited in part (c) of claim 1 .

4. The diketopiperazine of claim 3 wherein R 1 is the side chain of glycine, alanine, valine, leucine or isoleucine.

5. The diketopiperazine of claim 1 wherein n is 1-3 and at least one R 5 is an aryl, heteroaryl or aryloxy.

6. The diketopiperazine of claim 5 wherein R 5 is an aryl or aryloxy.

7. The diketopiperazine of claim 6 wherein R 5 is phenyl.

8. The diketopiperazine of claim 6 wherein R 5 is phenoxy.

9. The diketopiperazine of claim 1 wherein n is 1 and R 5 is in the 4 (para) position on the ring.

10. The diketopiperazine of claim 1 wherein R 2 has formula II.

11. The diketopiperazine of claim 1 wherein R 2 has formula III.

12. The diketopiperazine of claim 1 wherein R 6 is methyl.

13. The diketopiperazine of claim 1 which is biphenyl-4-yl-(3,6-dioxo-piperazin-2-yl)-acetic acid methyl ester.

14. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and an active ingredient, wherein the active ingredient is a diketopiperazine according to any one of claims 1 - 13 or a pharmaceutically-acceptable salt or thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2013
From: DMI ACQUISITION CORP.
To: AMPIO PHARMACEUTICALS, INC.
Reel/Frame 031305/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF ASSIGNEE. THE ASSIGNEE HAS SINCE CHANGED LOCATIONS. PREVIOUSLY RECORDED ON REEL 024905 FRAME 0070. ASSIGNOR(S) HEREBY CONFIRMS THE FOLLOWING "AT THE REQUEST OF THE ASSIGNEE DO SELL, ASSIGN, AND TRANSFER UNTO SAID ASSIGNEE . . .". Recorded Feb 16, 2011
From: BAR-OR, DAVID
To: DMI ACQUISITION CORP.
Reel/Frame 025810/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2010
From: BAR-OR, DAVID
To: DMI ACQUISITION CORP.
Reel/Frame 024905/0070 →